Filter by Year:
Press Releases
-
Nov 22, 2022
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
-
Nov 14, 2022
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
-
Nov 09, 2022
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
-
Nov 08, 2022
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
-
Oct 27, 2022
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
-
Oct 26, 2022
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
-
Oct 20, 2022
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
-
Sep 27, 2022
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
-
Sep 01, 2022
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Aug 31, 2022
Foghorn Therapeutics Announces Change to Board of Directors
Displaying 21 - 30 of 69